eCORE
- Advanced Therapies and Advanced Interventions, Nanomedicine, Transplant & Donation
- Chronic, Prevalent Diseases & Aging
- Woman & Child Health & Rare Diseases
Team
Group Leader
José García Arumí
Principal Investigator (PI)
Anna Duarri, Anna Boixadera Espax, Miguel Angel Zapata Victori, Miguel Ángel Arcediano
PhD Students
Maddalen Zufiaurre Seijo, Helena Isla Magrané, Laura Natalia Distefano
Lab Technicians
Alfredo Pueyo Ferrer, Marta Garrido Marin, Eric Kirkegaard Biosca, Jorge Fernandez Engroba, Helena Brosa Morros, Jaume Rigo Quera, Alba Gil Loyo, Pere Marc Almagro Muriana, Ferran Casals Riera, Gemma Gervilla Diaz, Lidia Martin Firvida, Mariona Fons i Castells
Nursing and Technical Staff
Mireia Campius Piñas
Selected Publications
Llorián-Salvador M, Pérez-Martínez D, Tang M, Duarri A, García-Ramirez M, Deàs-Just A, Álvarez-Guaita A, Ramos-Pérez L, Bogdanov P, Gomez-Sanchez JA, Stitt AW, Hernández C, de la Fuente AG, Simó R
Regulatory T cell expansion prevents retinal degeneration in type 2 diabetes
J Neuroinflammation. 2024 Dec 23;21(1):328
DOI: 10.1186/s12974-024-03323-0
IF: 9.3
Pinteac R, Soriano J, Matute-Blanch C, Lizcano JM, Duarri A, Malhotra S, Eixarch H, López Comellas G, Montalban X, Comabella M
Chitinase 3-like 1 is neurotoxic in multiple sclerosis patient-derived cortical neurons
Clin Transl Med. 2024 Dec;14(12):e70125
DOI: 10.1002/ctm2.70125
IF: 7.9
Puzo M, Calvo-Perez P, Bartol-Puyal F, Sanchez-Monroy J, Martin-Pinardel R, Parrado-Carrillo A, Moll-Udina A, Bernal-Morales C, Sanchez-Vela L, Sararols-Ramsay L, Garay-Aramburu G, Arruabarrena C, García-Arumí J, Abraldes M, Ruiz-Moreno JM, Valldeperas X, Velázquez-Villoria D, Escobar-Barranco JJ, Gallego-Pinazo R, Figueroa MS, Figueras-Roca M, Barthelmes D, Gillies MC, Casaroli-Marano RP, Zarranz-Ventura J
Fight Retinal Blindness SPAIN. Report 3: clinical outcomes of vascular endothelial growth factor inhibitors in low vision eyes with neovascular age-related macular degeneration. A national database study
Eye 38, 3450–3458 (2024)
DOI: 10.1038/s41433-024-03322-8
IF: 3.9
Sánchez-Vela L, García-Arumí Fusté C, Castany-Aregall M, Subirà-González O, Ruiz-Casas D, de-Arriba-Palomero P, García-Arumí J
Reverse Pupillary Block after Implantation of a Sutureless Scleral Fixation Carlevale Intraocular Lens.
Ophthalmol Retina. 2024 Oct 15:S2468-6530(24)00475-5
DOI: 10.1016/j.oret.2024.10.004
IF: 4.3
Izquierdo-Serra J, Martin-Pinardel R, Moll-Udina A, Bernal-Morales C, Garay-Aramburu G, Sanchez-Monroy J, Arruabarrena C, Fernandez-Hortelano A, Figueroa MS, Abraldes M, Lavid de Los Mozos FJ, Zapata MA, Ruiz-Moreno JM, Broc-Iturralde L, Gonzalez-Guijarro J, Escobar-Barranco JJ, Gallego-Pinazo R, Parrado-Carrillo A, Dotti-Boada M, Alforja S, Figueras-Roca M, Barthelmes D, Gillies MC, Casaroli-Marano RP, Zarranz-Ventura J
Macular Neovascularization Type Influence on Anti-VEGF Intravitreal Therapy Outcomes in Age-Related Macular Degeneration.
Ophthalmol Retina. 2024 Apr;8(4):350-359
DOI: 10.1016/j.oret.2023.10.022
IF: 4.3
Selected Projects
A new formulation of cerium oxide nanoparticles as adjuvant for retinal anti-angiogenesis therapy
Principal Investigator: Victor Puntes
Agency: AGAUR
Funding: 150,000 €
Period: 2023-2025
RETVISION: From molecular genetic diagnosis to advanced therapies to treat retinal degenerative diseases
Principal Investigator: José García Arumí
Agency: ISCIII
Funding: 123,420 €
Period: 2023-2025
Análisis masivo de datos de bioimagen para el desarrollo de terapias celulares para enfermedades degenerativas de la retina (Digital Retina)
Principal Investigator: Miguel Ángel Zapata
Agency: MINISTERIO DE CIENCIA E INNOVACIÓN
Funding: 188,760 €
Period: 2022-2025
Red de Enfermedades Inflamatorias (RICORS).
Principal Investigator: José García Arumí
Agency: ISCIII
Funding: 121,350 €
Period: 2022-2025
CELLUX: CeO2 Nanoparticles-assisted stem cell therapy: an innovative nanopharmaceutical approach to treat retinal degenerative diseases.
Principal Investigator: Anna Duarri
Agency: Euronanomed III - ISCIII
Funding: 174,845 €
Period: 2022-2024
Patents
OPHTHALMIC TOPICAL COMPOSITION WITH CERIA NANOPARTICLES FOR TREATING DISEASES OF POSTERIOR SEGMENT OF THE EYE
Priority Number: PCT/EP2022/059891
Priority Date: 15/04/2021
Applicants: 77.5% VHIR, 15% ICREA, 7.5% ICN2
Disolución coloreada en particular para el uso en métodos quirúrgicos para el tratamiento de los cuerpos de seres humanos o animales
Priority Number: EP 2827911
Priority Date: 19.03.2012
Applicants: 100% AL.CHI.MI.A. S.R.L.
